← Research library

Imunofan alongside multimodal breast cancer treatment in Samara

Comparison in people · 2004

What was studied
174 patients with breast cancer treated in Samara from 2001 to 2003, 92 with adjunctive Imunofan and 82 controls.
Main finding
Local postoperative complications · 20/92 (21.7%) with Imunofan versus 24/82 (29.3%) with standard care, calculated from the reported counts. The printed p<0.01 does not agree with a simple comparison of those counts.

Reported findings and study design

Reported findings

The author abstract reports 50 µg (1 mL of 0.005% solution) intramuscularly daily for five days, in three courses after radiotherapy, after mastectomy and between chemotherapy cycles two and three. Total reported exposure was 750 µg.

Population or model 174 patients with breast cancer treated in Samara from 2001 to 2003, 92 with adjunctive Imunofan and 82 controls.

Dose, route and schedule

The author abstract reports 50 µg (1 mL of 0.005% solution) intramuscularly daily for five days, in three courses after radiotherapy, after mastectomy and between chemotherapy cycles two and three. Total reported exposure was 750 µg.

Protocol source ↗ · Author abstract methods, Table 1 and the stage IIIA clinical results.

Results · Author abstract methods, Table 1 and the stage IIIA clinical results.
MeasureResultComparison, timing and statistics
Local postoperative complications20/92 (21.7%) with Imunofan versus 24/82 (29.3%) with standard care, calculated from the reported counts. The printed p<0.01 does not agree with a simple comparison of those counts.
Lymph drainage lasting over 10 days16/92 (17.4%) versus 19/82 (23.2%), calculated from the reported counts.
Wound suppuration2/92 versus 2/82. The author abstract describes no clear overall difference in wound complications.
Stage IIIA leukopenia during chemotherapy3/20 versus 6/19, reported in the stage-specific comparison.

Randomization and blinded assessment were not reported. The author abstract gives inconsistent percentages, subgroup denominators and significance statements. Differences in treatment tolerance cannot establish tumor control or survival benefit.

Source for these results ↗ · Reviewed 2026-11-14

Study limitations and source details

Study limitations

  • Randomization and blinded assessment were not reported. The author abstract gives inconsistent percentages, subgroup denominators and significance statements. Differences in treatment tolerance cannot establish tumor control or survival benefit.

Related publications may describe some of the same participants or experiments.

Source details

Original dissertation author abstract

Author abstract methods, Table 1 and the stage IIIA clinical results.

Sources checked

Added to the library

Citation

Human comparative studyFull text available

T. G. Zolotareva. Imunofan alongside multimodal breast cancer treatment in Samara Candidate dissertation author abstract, Samara State Medical University, defended in Ufa, 2004.

Study source ↗ · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards